Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company specializing in the research, development, and marketing of novel therapies targeting the complement system—an integral part of the immune response. The company is recognized for its innovative focus on treating rare and serious diseases with high unmet medical need, particularly those stemming from autoimmune and inflammatory processes. Its notable products include EMPAVELI, approved for paroxysmal nocturnal hemoglobinuria, and SYFOVRE, designed for geographic atrophy associated with age-related macular degeneration. Apellis’s pipeline extends to treatments for other complement-mediated disorders, with investigational candidates such as siRNA-based APL-3007 and preclinical oral complement inhibitors. The firm leverages alliances with entities like Swedish Orphan Biovitrum and Beam Therapeutics to further its research and commercial reach in rare disease therapeutics. Since its founding in 2009, Apellis Pharmaceuticals has established a significant presence in the biotechnology sector, addressing critical gaps in care through advanced complement inhibition technology.